<DOC>
	<DOCNO>NCT00924105</DOCNO>
	<brief_summary>The purpose clinical trial test safety tolerability vaccine target Interleukin-1 beta patient type 2 diabetes .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacodynamics CYT013-IL1bQb Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus , accord American Diabetes Association diagnostic criterion , ≥ 3 month time randomization HbA1c range 6.5 9.5 % ( inclusive ) screen Treatment diet exercise alone stable dose metformin , sulfonylurea , metformin plus sulfonylurea least 4 week prior randomization Further criterion define clinical trial protocol Symptoms hyperglycemia ( i.e . polyuria polydypsia ) History significant weight gain loss ( +/5 % ) 4 week randomization Fasting Cpeptide level &lt; 400 pmol/L screen Change medicamentous treatment elevate blood pressure , diabetes mellitus dyslipidemia within 4 week prior randomization Use weight loss medication ( counter prescription ) initiation prescribe weight management exercise program within 4 week randomization Current systemic antiinflammatory therapy aspirin ≤ 100 mg/day immunosuppressive treatment , particular oral corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>